SAR Exploration Guided by LE and Fsp(3): Discovery of a Selective and Orally Efficacious RORγ Inhibitor.

A novel series of RORγ inhibitors was identified starting with the HTS hit 1. After SAR investigation based on a prospective consideration of two drug-likeness metrics, ligand efficiency (LE) and fraction of sp(3) carbon atoms (Fsp(3)), significant improvement of metabolic stability as well as reduction of CYP inhibition was observed, which finally led to discovery of a selective and orally efficacious RORγ inhibitor 3z.

[1]  Peter Lockey,et al.  Minor Structural Change to Tertiary Sulfonamide RORc Ligands Led to Opposite Mechanisms of Action. , 2015, ACS medicinal chemistry letters.

[2]  Bohdan Waszkowycz,et al.  A reversed sulfonamide series of selective RORc inverse agonists. , 2014, Bioorganic & medicinal chemistry letters.

[3]  T. Schlüter,et al.  Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORβ and RORγt. , 2014, Bioorganic & medicinal chemistry letters.

[4]  Adam R. Johnson,et al.  Reduction in lipophilicity improved the solubility, plasma-protein binding, and permeability of tertiary sulfonamide RORc inverse agonists. , 2014, Bioorganic & medicinal chemistry letters.

[5]  Adam R. Johnson,et al.  Identification of tertiary sulfonamides as RORc inverse agonists. , 2014, Bioorganic & medicinal chemistry letters.

[6]  B. Fauber,et al.  Modulators of the nuclear receptor retinoic acid receptor-related orphan receptor-γ (RORγ or RORc). , 2014, Journal of medicinal chemistry.

[7]  J. D. Elliott,et al.  Discovery of novel N-(5-(arylcarbonyl)thiazol-2-yl)amides and N-(5-(arylcarbonyl)thiophen-2-yl)amides as potent RORγt inhibitors. , 2014, Bioorganic & medicinal chemistry.

[8]  J. D. Elliott,et al.  Discovery of Tertiary Amine and Indole Derivatives as Potent RORγt Inverse Agonists. , 2014, ACS medicinal chemistry letters.

[9]  Adam R. Johnson,et al.  Structure-based design of substituted hexafluoroisopropanol-arylsulfonamides as modulators of RORc. , 2013, Bioorganic & medicinal chemistry letters.

[10]  P. Griffin,et al.  Synthetic modulators of the retinoic acid receptor-related orphan receptors , 2013 .

[11]  F. Lovering,et al.  Escape from Flatland 2: complexity and promiscuity , 2013 .

[12]  Ruben D. Garcia-Ordonez,et al.  Small molecule amides as potent ROR-γ selective modulators. , 2013, Bioorganic & medicinal chemistry letters.

[13]  Ruili Huang,et al.  Identification of Potent and Selective Diphenylpropanamide RORγ Inhibitors. , 2013, ACS medicinal chemistry letters.

[14]  P. Griffin,et al.  Identification of a selective RORγ ligand that suppresses T(H)17 cells and stimulates T regulatory cells. , 2012, ACS chemical biology.

[15]  P. Griffin,et al.  Identification of SR2211: a potent synthetic RORγ-selective modulator. , 2012, ACS chemical biology.

[16]  Scott A. Busby,et al.  The Benzenesulfoamide T0901317 [N-(2,2,2-Trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] Is a Novel Retinoic Acid Receptor-Related Orphan Receptor-α/γ Inverse Agonist , 2010, Molecular Pharmacology.

[17]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[18]  C. Abad-Zapatero,et al.  Ligand efficiency indices for effective drug discovery , 2007, Expert opinion on drug discovery.

[19]  D. Littman,et al.  The Orphan Nuclear Receptor RORγt Directs the Differentiation Program of Proinflammatory IL-17+ T Helper Cells , 2006, Cell.

[20]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[21]  Ying Wang,et al.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 , 2005, Nature Immunology.

[22]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[23]  Aaron S. Anderson,et al.  Discovery and SAR of trisubstituted thiazolidinones as CCR4 antagonists. , 2004, Bioorganic & medicinal chemistry letters.

[24]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[25]  I. Kuntz,et al.  The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Qihong Zhao,et al.  Chapter Twelve - Targeting the Nuclear Hormone Receptor RORγt for the Treatment of Autoimmune and Inflammatory Disorders , 2013 .